Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26 2022 - 7:00AM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function, today announced the appointment of
Steven E. Hyman, M.D., to its Board of Directors effective July 25.
Dr. Hyman will work with Cyclerion leadership to help shape the
future of its research and clinical development strategy while
expanding external collaborations with scientific leaders and
industry partners.
“We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve
is a world-renowned leader in neuroscience with deep expertise
leading large-scale, collaborative research programs aimed to
discover and develop novel biomarkers and therapeutics for
neuropsychiatric diseases. His experience will be instrumental as
we advance our lead molecule, CY6463, and continue to build our
pipeline,” said Peter Hecht, Ph.D., Chief Executive Officer of
Cyclerion. “We seek board members with strong strategic judgment,
an owner-oriented mindset, business savvy, a strong interest in our
company, and absolute integrity, and Steve embodies all of those
attributes and will serve as an outstanding representative of our
shareholders and advisor to our company.”
“Despite significant advances in our understanding of the
genetic and biological basis of neuropsychiatric diseases, there
remains an urgent need to translate such advances into meaningful
new therapies for patients. Cyclerion’s lead asset, CY6463, targets
a central node of brain physiology and has the potential to address
a broad range of diseases characterized by cognitive dysfunction,”
said Dr. Hyman. “I look forward to working closely with Cyclerion
leadership to help maximize the potential of the portfolio to
address unmet patient needs.”
Dr. Hyman is a Distinguished Service Professor and the Harald
McPike Professor of Stem Cell and Regenerative Biology at Harvard
University and a Core Institute Member of the Broad Institute of
MIT and Harvard, where he directs the Stanley Center for
Psychiatric Research. Dr. Hyman also serves as Chairman of the
Board of Directors of the Charles A. Dana Foundation, which
supports research and education in neuroscience. In the private
sector, he is founder of Emugen Therapeutics, a Director of Voyager
Therapeutics and Q-State Biosciences, and serves on the scientific
advisory boards of Janssen Pharmaceuticals and F-Prime Capital.
From 2001 to 2011 Dr. Hyman served as Provost of Harvard
University. From 1996 to 2001, he served as Director of the
National Institute of Mental Health where he emphasized investment
in neuroscience and emerging genetic technologies. He has served as
Editor of the Annual Review of Neuroscience (2002-2016), founding
President of the International Neuroethics Society (2008-2013),
President of the Society for Neuroscience (2015), and President of
the American College of Neuropsychopharmacology (2018). He is a
fellow of the American Academy of Arts and Sciences, a fellow of
the American Association for the Advancement of Science, and a
member of the National Academy of Medicine. Dr. Hyman received his
B.A., summa cum laude, from Yale College, an M.A. from the
University of Cambridge, which he attended as a Mellon fellow
studying History and Philosophy of Science, and an M.D., cum laude,
from Harvard Medical School.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical
company on a mission to develop treatments that restore cognitive
function. Cyclerion’s lead molecule is CY6463, a novel,
first-in-class, CNS-penetrant, sGC stimulator that modulates a key
node in a fundamental CNS signaling network. The multidimensional
pharmacology elicited by the stimulation of sGC has the potential
to impact a broad range of CNS diseases. CY6463 has shown rapid
improvement in biomarkers associated with cognitive function and is
currently in clinical development for Alzheimer's Disease with
Vascular pathology (ADv) and Mitochondrial Encephalomyopathy,
Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive
Impairment Associated with Schizophrenia (CIAS). Cyclerion is also
advancing CY3018, a next generation sGC stimulator.
For more information about Cyclerion, please visit
https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion)
and LinkedIn (www.linkedin.com/company/cyclerion).
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Our forward-looking statements are based on current
beliefs and expectations of our management team that involve risks,
potential changes in circumstances, assumptions, and uncertainties.
We may, in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Each forward-looking statement is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks
and uncertainties include the risks listed under the heading “Risk
Factors” and elsewhere in our 2021 Form 10-K filed on February 24,
2022, and subsequent filings. Investors are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements (except as otherwise noted) speak only
as of the date of this press release, and Cyclerion undertakes no
obligation to update these forward-looking statements, except as
required by law.
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Jul 2023 to Jul 2024